GLP1R and type 2 diabetes mellitus: A review of CVOTs completed between 2008 and 2016 demonstrated that new glucose-lowering drugs such as dipeptidyl peptidase 4 (DPP4) inhibitors (saxagliptin, alogliptin and sitagliptin), glucagon-like peptide 1 (GLP-1) receptor agonists (lixisenatide, liraglutide, and semaglutide) and sodium-glucose co-transporter 2 (SGLT-2) inhibitor (empagliflozin) do not increase the CV risk in patients with T2D compared to standard of care (SoC) [13].